Clinical Trial Update: A Phase 2 Study of Standard Chemotherapy Plus BSI-201 (a PARP Inhibitor) in the Neoadjuvant Treatment of Triple Negative Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating standard chemotherapy plus BSI-201 (iniparib) as neoadjuvant therapy for triple-negative breast cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• BSI-201 (iniparib)

Snippet

Sponsor: Sanofi | Conditions: Triple Negative Breast Cancer | Phase 2 | Status: COMPLETED